⌕
Amplify Weight Loss Drug & Treatment ETF · THNR · NYSE Arca
Broad equity exposure · not Tenet-scored
Compare
$25.76−1.44%At close
$25.76−0.38 (−1.44%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE Arca · USD

Amplify Weight Loss Drug & Treatment ETF (THNR) Price

Sources Fund holdings disclosures and market prices Fund disclosures and pricesPrice as of How we compute thisNot investment advice

Price

Loading chart…

Price return, distributions not included.

Snapshot

Equity · BlendIssuer: Amplify
Expense ratio
0.59%
annual fee
Assets
$5.2M
under management
Holdings
22
positions
Distribution yield (TTM)
1.6%
as of Nov 13, 2026
Inception
2024
launch year

We hold no record of the date this NAV was struck.

THE VERDICT

Broad equity exposure. At a 0.59% fee and 1.6% distribution yield, the fee eats into returns over time. Its largest tilt is Healthcare (~100%).

This label comes from the fund's own properties: what it holds, its category, asset class, expense ratio, yield, leverage and whether it pays regular income. Nothing about the reader enters it, and it is not the Tenet Score.

At a glance

the case for and against

Why own it

▲Provides single-ticket exposure to its slice of the market.

Watch out for

▼Concentrated tilt: Healthcare make up ~100% of the basket.
▼Higher cost. A 0.59% expense ratio eats into returns over time.
▼Young fund: launched 2024, limited through-cycle history.

Best suited for

Investors who want a broad basket of stocks in one fund.

Basket · as of Nov 9, 2026

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.